Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com -- Laboratorios Farmaceuticos shares climbed 5% after the company raised its fiscal year 2025 guidance for enoxaparin sales, now expecting a mid-single-digit increase versus a previously forecasted low-single-digit decrease.
The pharmaceutical company’s revised outlook for its enoxaparin business is projected to improve group sales by approximately 1.1%. The company’s low-molecular-weight heparin (LMWH) business was a strong growth contributor in the first half of the year, increasing by 12% YoY, with enoxaparin and bemiparin performing well.
For the first half of fiscal 2025, Laboratorios Farmaceuticos reported operating revenues of €314.6 million, a 4.5% decrease compared to the same period last year, matching analyst consensus of €314.5 million. The specialty pharma business grew 12.8% to €237.4 million, partially offsetting the 35.1% decline in the contract development and manufacturing organization (CDMO) segment, which fell to €77.2 million.
Gross margin improved to 62.4% from 59.4% in the prior-year period, exceeding consensus estimates of 61.0%. The margin expansion was driven by increased contribution from high-margin Okedi products and a 33% decrease in LMWH raw material prices.
EBITDA decreased 6.2% to €65.6 million, with margins contracting to 20.9% from 21.2% in the first half of fiscal 2024, primarily due to increased R&D spending. Despite this, the company’s EBITDA still surpassed analyst expectations of €63.1 million.
For the full fiscal year 2025, Laboratorios Farmaceuticos reiterated its guidance for operating revenue to decrease by a mid-single-digit percentage compared to 2024, while updating its bemiparin forecast to grow by a low single digit versus the previous year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.